Single-Ascending Dose Study of JK07 in Subjects With HFpEF

Heart Failure With Preserved Ejection Fraction Clinical Trial

Official title: A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Assess the Safety and Tolerability of JK07 in Subjects With Heart Failure With Preserved Ejection Fraction (HFpEF)

Status Withdrawn

Clinical Trial Summary

A phase 1, randomized, double-blind, placebo-controlled single-ascending dose study to assess JK07 in adult subjects with heart failure with preserved ejection fraction.

Clinical Trial Description

A phase 1, randomized, double-blind, placebo-controlled single-ascending dose study to assess the safety and tolerability of JK07 in subjects 18 to 85 years of age with heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction >=45%. Eligible subjects must have maintained an optimal heart failure medical regimen for at least 1 month prior to informed consent, other than for diuretics, and as much as clinically appropriate, remain on the treatment regimen throughout the course of the study. Initially 5 dose escalation cohorts are planned with the option of expansion to 7 dose escalation cohorts. Eight subjects will be randomized in a 6:2 ratio of JK07:placebo in each cohort. The initial dose and dose escalation parameters will be dependent on the JK07.1.01 study Only doses established as safe in Study JK07.1.01 will be evaluated in this study and the highest JK07 dose administered will not exceed the lower of the top dose evaluated in Study JK07.1.01 or 2.5 mg/kg without amending the protocol. Subjects will be observed in a hospital or similar setting from prior to study drug infusion to completion of study assessments on Day 1. Subjects will undergo blood sampling for clinical laboratory evaluation, including glucose fingerstick, and biomarkers, electrocardiogram, 2-dimensional transthoracic echocardiography, quality of life assessment and a a 6-minute walking test. Follow-up assessments will be performed at Day 2, 7, 15, 28, 60, 90, and 180. ;

Related Conditions & MeSH terms

• Heart Failure
• Heart Failure With Preserved Ejection Fraction

• NCT number: NCT05322616
• Study type: Interventional
• Source: Salubris Biotherapeutics Inc
• Status: Withdrawn
• Phase: Phase 1
• Start date: October 21, 2022
• Completion date: May 26, 2023